This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Recent Outbreak Of Hand-Foot-Mouth Disease In 2.2 Million Children (WHO) Preceded And Predicted By Increase In The HFMD Genomic Replikin® Count

LONDON, Feb. 19, 2013 /PRNewswire/ -- Bioradar UK Ltd has found that the virus genomic Replikin ® Count in Hand-Foot-Mouth Disease (HFMD) increased fourfold worldwide from 2005 to 2012 (Figure). All HFMD genomes on Pubmed were analyzed for Replikins (References). Increase in the genomic Replikin ®Count (number of genomic Replikins per 100 amino acids) alone preceded and predicted the increases in the number of cases (p<0.001).

(Photo:  http://photos.prnewswire.com/prnh/20130219/PH62841 )

From 2010 to 2011, Counts exceeding 4.0 appeared and have since continued to increase in percent of the total virus population. There were 30,000 cases in China in 2008 and 2.2 million in 2012 (WHO). Genomic Replikin ®Counts, alone, have now been correct 12 successive times in different virus species and strains at predicting outbreaks (References). Replikin ®Count prediction has permitted the design of solid phase completely synthetic Replikins HFMD Vaccine.   

Contact: sbogoch@replikins.com, Tel 646-320-5910

References:

  1. Nature Precedings (8 Bogoch publications): http://precedings.nature.com/users/549471c7b195af1864d2f1b1996f6064
  2. website http://www.replikins.com  

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 

SOURCE Replikins

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs